理舒望®血塞通软胶囊临床应用专家共识
本共识由中华中医药学会发布(编号GS/CACM 323-2023),遵循《中成药临床专家共识制定技术规范》,采用名义组法形成19条推荐意见/共识建议。文件针对缺血性卒中及冠心病心绞痛,提出血塞通软胶囊的用药时机、辨证用药、疗效、用法用量、疗程、经济性及安全性等推荐。适用于各级医疗机构内科、脑病(神经内)科、心血管科、老年科、急诊科、全科及中医科医生,以及医院和药店药师,作为使用该药的参考。
要点
- 共识形成19条推荐意见/共识建议,涵盖缺血性卒中与冠心病心绞痛使用血塞通软胶囊的时机、辨证、疗程、剂量及安全性。
- 血塞通软胶囊具有活血化瘀、通脉活络功效,临床广泛用于心脑血管疾病防治,对缺血性卒中、冠心病等显示显著疗效。
- 该药已被多个指南、共识及专著推荐,本共识由中华中医药学会发布,编号GS/CACM 323-2023。
- 适用读者包括各级医疗机构内科、脑病(神经内)科、心血管科、老年科、急诊科、全科及中医科医生,以及医院和药店药师。
适用人群与场景
- 适用于各级医疗机构内科、脑病(神经内)科、心血管科、老年科、急诊科、全科及中医科医生,以及医院和药店药师,作为使用血塞通软胶囊的用药参考。
- 临床用于缺血性卒中、冠心病心绞痛等心脑血管疾病的防治。
处置流程与药物剂量
- 共识提出了血塞通软胶囊治疗缺血性卒中及冠心病心绞痛时的用药时机、辨证用药、疗效、用法用量、疗程、经济性及安全性等推荐意见,具体剂量与疗程见原文推荐意见。
研究设计与关键结果
- 共识遵循中华中医药学会《中成药临床专家共识制定技术规范》,采用名义组法形成19条推荐意见/共识建议。
- 共识已由中华中医药学会审查发布,编号GS/CACM 323-2023。
证据类型、等级与局限
- 证据类型:专家共识;制定方法为名义组法,遵循《中成药临床专家共识制定技术规范》。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识旨在规范血塞通软胶囊在缺血性卒中及冠心病心绞痛中的临床应用,提高临床疗效、促进合理用药并降低用药风险。
指南或共识出处
- 共识名称:理舒望®血塞通软胶囊临床应用专家共识;发布机构:中华中医药学会;编号GS/CACM 323-2023。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Lixuwang~® Xuesaitong Soft Capsules(referred to as "Xuesaitong Soft Capsules") have the effects of promoting blood circulation, resolving blood stasis, and dredging meridians and collaterals. They are widely used in the prevention and treatment of cardiovascular and cerebrovascular diseases in clinical practice. Through years of clinical observation, they have shown significant efficacy in ischemic stroke, coronary heart disease, and other diseases, and have been recommended by multiple guidelines, consensus statements, and monographs. Based on the summary of clinical application experience by doctors and existing evidence-based research, following the Technical Specifications for Consensus Development of Chinese Patent Medicine by Clinical Experts issued by Standardization Office of the Chinese Association of Traditional Chinese Medicine, a nominal group method was used to reach 19 recommended opinions/consensus suggestions. This document proposes the timing of medication, syndrome differentiation for medication, therapeutic effects, dosage and administration, treatment duration, economic considerations, and safety considerations in the use of Xuesaitong Soft Capsules for the treatment of ischemic stroke and angina pectoris in coronary heart disease. It is intended for doctors in internal medicine, encephalopathy(neurology), cardiovascular medicine, geriatrics, emergency medicine, general practice, and traditional Chinese medicine departments of various medical institutions, as well as pharmacists in hospitals and pharmacies, as a medication reference when using Xuesaitong Soft Capsules. It is hoped that the widespread application of this consensus can improve the clinical efficacy of Xuesaitong Soft Capsules in the treatment of ischemic stroke and coronary heart disease, promote rational drug use, and reduce medication risks. This consensus has been reviewed and published by the China Association of Traditional Chinese Medicine, with the identification number GS/CACM 323-2023.
参考来源
- Jia M, Liang X, Fu GJ, et al. [Expert consensus on clinical application of Lixuwang~® Xuesaitong Soft Capsules]. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114160. doi:10.19540/j.cnki.cjcmm.20230630.501
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。